DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Myelodysplastic Syndrome market report provides current treatment practices, emerging drugs, Myelodysplastic Syndrome market share of the individual therapies, and current and forecasted Myelodysplastic Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Myelodysplastic Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Myelodysplastic Syndrome market.
Some of the Key Facts of the Myelodysplastic Syndrome Market Report
-
According to the American Cancer Society, the number of people diagnosed with MDS in the US each year is unknown. However, some estimates have put this number at about 10,000, while other estimates have been much higher. Moreover, MDS is uncommon before age 50, and the risk increases as a person gets older. It is also most commonly diagnosed in people in their 70s, and the number of new cases diagnosed each year is likely increasing as the average age of the US population increases.
-
A study on clinical manifestations and diagnosis of MDS by Aster and Stone (2020) stated that MDS occurred most commonly in older adults, but the precise incidence was not well-defined. The median age at presentation is 70 years, and disease onset before age 50 is unusual (except for therapy-related MDS), and rare cases had been reported in children. Moreover, the risk of developing MDS increased with age. The study also quoted that the annual incidence per 100,000 was estimated to be 0.5, 5.3, 15, 49, and 89 for individuals <50, 50–59, 60–69, 70–79, and ≥80 years of age, respectively, and there is a male predominance in most categories of MDS, except MDS with isolated del (5q), which is more common in women. Moreover, the annual incidence of MDS has been estimated to be 1–5 cases per 100,000; however, for individuals aged >70 years, the incidence is at least 20 cases/per 100,000. However, due to underreporting of MDS in most cancer registries, the true annual incidence in individuals >65 years of age may be closer to 75 cases/100,000.
Got queries? Click here to know more about the Myelodysplastic Syndrome Market Landscape
Myelodysplastic Syndrome Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. In MDS, also known as myelodysplasia, the bone marrow cells do not develop into mature blood cells; instead, these cells stay within the bone marrow in an immature state. There are many subtypes of MDS; some cases are mild, while others are more severe and carry a high risk of becoming acute myelogenous leukemia (AML).
MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable. Not all patients require treatment initially, as there is no survival benefit with the treatment of asymptomatic, low-risk patients. There are many subtypes of MDS. The subtype is determined using the results of blood and bone marrow tests. MDS subtype is determined using either the World Health Organization (WHO) classification system or the French-American-British (FAB) classification system, but the WHO classification is more commonly used today.
Myelodysplastic Syndrome Epidemiology Insights
-
The total incident population of MDS in the 7MM was 41,850 in 2021, growing at a CAGR of 0.6% during the study period (2019–2032).
-
As per Delveinsight’s analysis, the United States accounted for 20,633 incident cases of MDS in 2021 which was the highest among the 7MM.
-
In the US, the age group of 80+ years accounted for the highest cases in 2021, followed by 70–79 years. In contrast, the least cases were found in the age group of 0–49 years. In 2021, there were 243, 1,081, 3,691, 7,356, and 8,263 cases, in the age groups 0–49 years, 50–59 years, 60–69 years, 70–79 years, and 80+ years, respectively.
-
Delveinsight also estimated that among EU5, the highest cases of the incident population was found to be in Germany with 4,520 incident cases of MDS in 2021 followed by France which had 4,391 incident cases of MDS. The least population with MDS in 2021 was found to be in Spain which had around 2,016 incident cases of MDS.
-
In the US, based on the IPSS scoring, Low-risk MDS and Very high-risk MDS accounted for the highest (7,180) and lowest cases (3,363), respectively, in 2021.
-
Japan accounted for 3,913 incident MDS cases in 2021.
Myelodysplastic Syndrome Epidemiology Segmentation
-
Myelodysplastic Syndrome cases based on Incident Population
-
Myelodysplastic Syndrome subtype-specific Incident Population cases
-
Total Myelodysplastic Syndrome Mutation Specific Incident Population cases
Myelodysplastic Syndrome Market Outlook
The Myelodysplastic Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Myelodysplastic Syndrome market trends by analyzing the impact of current Myelodysplastic Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of Myelodysplastic Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Myelodysplastic Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Myelodysplastic Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Myelodysplastic Syndrome Market Trends
Myelodysplastic Syndrome Key Companies
-
Fibrogen
-
Abbvie
-
Gilead Sciences
-
Novartis Pharmaceuticals
-
Syros Pharmaceuticals
-
And many others
Myelodysplastic Syndrome Therapies
-
Roxadustat (FG-4592)
-
Venclexta
-
Magrolimab ± Azacitidine
-
And many others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Myelodysplastic Syndrome
-
Disease Background and Overview
-
Epidemiology and patient population
-
The United States
-
EU 5
-
Myelodysplastic Syndrome Emerging Therapies
-
Myelodysplastic Syndrome Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Myelodysplastic Syndrome Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services